{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:18Z","timestamp":1789906638686,"version":"4.0.1"},"reference-count":32,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be considered as therapeutic options for refractory MG after insufficient symptom control by standard immunosuppressive therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective observational study, we included 57 rituximab-treated and 20 eculizumab-treated patients with MG to compare the efficacy of treatment agents in generalised, therapy-refractory anti-acetylcholine receptor antibody (anti-AChR-ab)-mediated MG with an observation period of 24 months. Change in the quantitative myasthenia gravis (QMG) score was defined as the primary outcome parameter. Differences between groups were determined in an optimal full propensity score matching model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both groups were comparable in terms of clinical and demographic characteristics. Eculizumab was associated with a better outcome compared with rituximab, as measured by the change of the QMG score at 12 and 24 months of treatment. Minimal manifestation of disease was more frequently achieved in eculizumab-treated patients than rituximab-treated patients at 12 and 24 months after baseline. However, the risk of myasthenic crisis (MC) was not ameliorated in either group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>This retrospective, observational study provides the first real-world evidence supporting the use of eculizumab for the treatment of refractory, anti-AChR-ab positive MG. Nonetheless, the risk of MC remained high and prompts the need for intensified monitoring and further research effort aimed at this vulnerable patient cohort.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-328665","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T18:20:32Z","timestamp":1646418032000},"page":"548-554","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Eculizumab versus rituximab in generalised myasthenia gravis"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-7143","authenticated-orcid":false,"given":"Christopher","family":"Nelke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-7880","authenticated-orcid":false,"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesa","family":"Regner-Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Huntemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menekse","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-6711","authenticated-orcid":false,"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmae","family":"Gassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Stetefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-4374","authenticated-orcid":false,"given":"Stefanie","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Vielhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"2023051800301768000_93.5.548.1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2023051800301768000_93.5.548.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"2023051800301768000_93.5.548.3","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2023051800301768000_93.5.548.4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"2023051800301768000_93.5.548.5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023051800301768000_93.5.548.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"2023051800301768000_93.5.548.7","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.4.1.43"},{"key":"2023051800301768000_93.5.548.8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"2023051800301768000_93.5.548.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"2023051800301768000_93.5.548.10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"2023051800301768000_93.5.548.11","unstructured":"Wiendl H . Diagnostik und therapie der myasthenia gravis und des lambert-eaton-syndroms, 2014."},{"key":"2023051800301768000_93.5.548.12","doi-asserted-by":"publisher","DOI":"10.1097\/00131402-200209000-00009"},{"key":"2023051800301768000_93.5.548.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489"},{"key":"2023051800301768000_93.5.548.14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"2023051800301768000_93.5.548.15","doi-asserted-by":"crossref","unstructured":"Thomsen JLS , Andersen H . Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol 2020;11.doi:10.3389\/fneur.2020.596382","DOI":"10.3389\/fneur.2020.596382"},{"key":"2023051800301768000_93.5.548.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012777"},{"key":"2023051800301768000_93.5.548.17","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000487"},{"key":"2023051800301768000_93.5.548.18","doi-asserted-by":"publisher","DOI":"10.2307\/2683092"},{"key":"2023051800301768000_93.5.548.19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"2023051800301768000_93.5.548.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116428"},{"key":"2023051800301768000_93.5.548.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"2023051800301768000_93.5.548.22","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.009"},{"key":"2023051800301768000_93.5.548.23","doi-asserted-by":"publisher","DOI":"10.1007\/82_2016_39"},{"key":"2023051800301768000_93.5.548.24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"2023051800301768000_93.5.548.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/295323","article-title":"Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome","volume":"2014","author":"Tsai","year":"2014","journal-title":"Adv Hematol"},{"key":"2023051800301768000_93.5.548.26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"2023051800301768000_93.5.548.27","unstructured":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study - The Lancet Neurology. Available: https:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422(17)30369-1\/fulltext [Accessed 7 Jun 2021]."},{"key":"2023051800301768000_93.5.548.28","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503"},{"key":"2023051800301768000_93.5.548.29","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002497"},{"key":"2023051800301768000_93.5.548.30","doi-asserted-by":"crossref","unstructured":"Patriquin CJ , Kulasekararaj A , Peffault de Latour R , et al . Prophylactic antibiotic use and risk of meningococcal infections in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab who received meningococcal vaccination: results from the International PNH registry. Blood 2019;134:4802.doi:10.1182\/blood-2019-127005","DOI":"10.1182\/blood-2019-127005"},{"key":"2023051800301768000_93.5.548.31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"2023051800301768000_93.5.548.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-328665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:04:18Z","timestamp":1700309058000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-328665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jnnp-2021-328665"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-328665","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}